Skip to main content
Erschienen in: Allergo Journal 2/2013

13.04.2013 | Original Article

Diamine oxidase determination in serum

Low assay reproducibility and misclassification of healthy subjects

verfasst von: Heidi S. Schnoor, Holger Mosbech, Per S. Skov, Lars K. Poulsen, Ph.D Bettina M. Jensen

Erschienen in: Allergo Journal | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten



Impaired histamine degradation based on reduced diamine oxidase (DAO) activity has been suggested to cause symptoms mimicking an allergic reaction.


To test whether patients presenting with possible histamine-induced symptoms have a low serum activity of DAO compared to healthy subjects.


Sera from 11 patients with a clinical history of potentially histamine-induced symptoms were included together with sera from 18 healthy subjects and 2 pregnant women having no such symptoms. The DAO activity in serum was quantified using a commercial enzyme immunoassay in three repeated measurements. A subset of sera was furthermore analyzed at a service laboratory.


Coefficients of variation between the three measurements of the individual sera were 5–138 %, with a mean of 35 %. The average deviation between the measured and the given value for a control sample included in the test kit was 86 %. Only 11 out of the 31 subjects were uniformly classified in all three runs. Among the healthy subjects, 9–12 out of 18 showed reduced or highly reduced activities; in the patient group, 0–5 out of 11 showed reduced or highly reduced activities in the three measurements. No significant differences were found between the healthy subjects and the patient group in two measurements, but one experiment surprisingly demonstrated a significantly lower mean level of activity, measured by histamine-degrading units (HDU/ml), for the healthy subjects. A subset of the sera were sent to a commercial service laboratory, and here too misclassification occurred. This could be due to reproducibility problems, since the same sample was divided into six aliquots and allocated into different classes in two of six cases.


The high interassay variation and perhaps an incorrectly defined normal range caused misclassification in more than half of the cases. Using a commercial immunoassay, it was not possible to distinguish healthy subjects from patients showing potentially histamine-induced symptoms.

  1. Demoncheaux JP, Michel R, Mazenot C, Duflos G, Iacini C, de LF et al. A large outbreak of scombroid fish poisoning associated with eating yellowfin tuna (Thunnus albacares) at a military mass catering in Dakar, Senegal. Epidemiol Infect 2012; 140: 1008–12PubMedView Article
  2. Schwelberger HG. Diamine oxidase (DAO) enzyme and gene. In: Falus A, editor. Histamine: Biology and Medical Aspects. Budapest: SpringMed Publishing, 2004; 43–52
  3. Klaus A, Weiss H, Nguyen JH, Margreiter R, Obrist P, Schwelberger HG. Histamine-degrading enzymes as cellular markers of acute small bowel allograft rejection. Transpl Int 2003; 16: 474–9PubMedView Article
  4. Wantke F, Hemmer W, Haglmuller T, Gotz M, Jarisch R. Histamine in wine. Bronchoconstriction after a double-blind placebo-controlled red wine provocation test. Int Arch Allergy Immunol 1996; 110: 397–400PubMedView Article
  5. Reese I, Ballmer-Weber B, Beyer K, Erdmann S, Fuchs T, Kleine-Tebbe J et al. Vorgehen bei Verdacht auf Unverträglichkeit gegenüber oral aufgenommenem Histamin. Allergo Journal 2012; 21: 22–8View Article
  6. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007; 85: 1185–96PubMed
  7. Wantke F, Proud D, Siekierski E, Kagey-Sobotka A. Daily variations of serum diamine oxidase and the influence of H1 and H2 blockers: a critical approach to routine diamine oxidase assessment. Inflamm Res 1998; 47(10):396–400.PubMedView Article
Diamine oxidase determination in serum
Low assay reproducibility and misclassification of healthy subjects
verfasst von
Heidi S. Schnoor
Holger Mosbech
Per S. Skov
Lars K. Poulsen
Ph.D Bettina M. Jensen
Urban and Vogel
Erschienen in
Allergo Journal / Ausgabe 2/2013
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405

Weitere Artikel der Ausgabe 2/2013

Allergo Journal 2/2013 Zur Ausgabe

AeDA/DGAKI informieren|Preisausschreibungen

Förderpreis „Spezifische Immuntherapie“

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.